
IN RE YAZ®, YASMIN®, OCELLA®
LITIGATION

SUPERIOR COURT OF NEW JERSEY
LAW DIVISION: BERGEN COUNTY

CASE NO. 287

FILED

CIVIL ACTION

JUL 22 2010

This Document Relates to All Actions

BRIAN R. MARTINOTTI, J.S.C.

CASE MANAGEMENT ORDER NO. 8

**DEFENDANTS' FACT SHEET ("DFS") AND
THE PRODUCTION OF SALES REPRESENTATIVE CUSTODIAL FILES**

This matter, having been opened to the Court by counsel for the Parties, and the Parties having consented, stipulated and agreed to the entry of this Case Management Order, and good cause appearing therefore;

IT IS, on this 22 day of July, 2010, hereby **ORDERED** as follows:

A. DEFENDANTS' FACT SHEET

1. In every case currently part of or later transferred or filed into the Superior Court of New Jersey, Law Division, as part of *In re YAZ®, Yasmin®, Ocella® Litig.*, Case No. 287¹, Defendants Bayer HealthCare Pharmaceuticals Inc., Bayer Schering Pharma AG, Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. shall provide fully responsive answers and documents to the Defendant Fact Sheet ("DFS"), in the form attached hereto as Exhibit 1, to Plaintiff's individual attorney as identified in the Plaintiff Fact Sheet, with a copy of the DFS (without documents) to Plaintiffs Liaison Counsel in paragraph A(8) below. As used herein the term "fully responsive" shall mean that each question in the DFS will be answered in detail and to the extent that an answer refers to a document, Bates-page number or a range of Bates page

¹ In the event that any future case alleging injury from ingestion of Gianvi is determined to be appropriate for inclusion in this coordinated proceeding, this Case Management Order will apply to the Pharmaceutical Company Defendants named and properly served in that case.

number shall be supplied which identify the document being referred to and produced.

Moreover, all documents supplied shall be Bates-numbered and shall be provided with the DFS consistent with Case Management Order No. 3, governing the format of production.

2. Within **forty-five (45) days** of the date of receiving a Plaintiff's Fact Sheet ("PFS") that contains the "Core Criteria" as defined below,² Defendants shall serve a DFS and all documents that are responsive to the DFS in an electronic format (except as provided in Section B below with regard to Sales Representative Custodial files, the production of which shall be staggered). If a PFS containing the "Core Criteria" has been served on Defendants prior to the date of this Order, Defendants shall have **forty-five (45) days** from the date of entry of this Order to complete and serve a DFS consistent with the provisions herein.

3. "Core Criteria" includes answers to the following question in the PFS attached to Case Management Order No. 7 as Exhibit 1:

- a) **PFS Sect. I:** Questions 1, 2 & 3 (Identification of Plaintiff and case the PFS is submitted in);
- b) **PFS Sect. III:** Question 4 (Identification of each pharmacy [name, address and the approximate years used] that has dispensed medication in the past ten (10) years, and corresponding signed authorizations). The lack of a pharmacy phone number or zip code is not considered a deficiency for the purpose of the production of a DFS; and
- c) **PFS Sect. IX:** Questions 1, 2 and 3 and corresponding signed authorizations (product use/prescriber information). The lack of a phone number

² The Parties expressly recognize that the "Core Criteria" used to trigger the production of a DFS are less than what is required for a PFS to be "substantially complete" as that term is defined in Case Management Order No. 7 § C and agree that the use of these "Core Criteria" is in no way meant to modify that definition of "substantially complete."

or zip code is not considered a deficiency for the purpose of the production of a DFS; and

d) **PFS Sect. X**: Questions 1(a) and (d) and corresponding signed authorizations (alleged injury information). It is sufficient in answering Question 1(a), for a Plaintiff to provide a short description of the injury alleged *i.e.* “Blood Clot,” “Pulmonary Embolism” or “PE,” “Deep Vein Thrombosis” or “DVT,” or “Gallbladder Injury,” “Stroke,” or “Heart Attack.” It is sufficient for Plaintiff to provide the month and year for her injury and Defendants shall not withhold a DFS if the month and year is provided.

e) **PFS Sect. XIII**: Plaintiff’s signature on PFS.

4. Defendants shall not delay the production of a DFS based on deficient “Core Criteria” absent good cause. If Defendants contend that any PFS does not satisfactorily include the “Core Criteria,” then Defendants shall, within either (i) **ten (10) days** after their receipt of the PFS, or (ii) **ten (10) days** after the date of this Order with respect to any PFS served on Defendants prior to the date of this Order, notify Plaintiff’s individual counsel by e-mail (with a copy of the e-mail to Plaintiff’s Liaison Counsel) of any alleged deficiency in the “Core Criteria” for processing the DFS. Failure to notify Plaintiff’s counsel within the ten (10) days shall mean that Defendants will provide a complete and verified DFS within forty-five (45) days after their receipt of the PFS.

5. If Defendants fail to provide a complete and verified DFS within the time period specified by paragraph 2, above, notice shall be given to Defendants by e-mail from either Plaintiff’s individual counsel or Plaintiffs’ Liaison Counsel, and Defendants shall have **twenty-**

one (21) days to cure the deficiency. Any claim of alleged deficiency with a DFS shall be directed by e-mail to:

Amy J. Roy
Eckert Seamans Cherin & Mellott, LLC
44th Floor, 600 Grant Street
Pittsburgh, PA 15219
YazDFS@eckertseamans.com

Jennifer La Mont, Esq.
Drinker Biddle & Reath LLP
500 Campus Drive
Florham Park, New Jersey 07932-1047
YasminDFS@dbr.com

6. Each Defendant named in Plaintiff's Complaint that has been properly served shall have a representative from the company sign the completed DFS and provide an executed declaration attesting that the information contained therein is true and correct to the best of the Defendant's knowledge, information and belief, formed after due diligence and reasonable inquiry.

7. A completed DFS shall be considered to be interrogatory answers and responses to requests for production under the Rules Governing the Court of New Jersey, and will be governed by the standards applicable to written discovery under the Rules Governing the Court of New Jersey. The interrogatories and requests for production in the DFS shall be answered without objection.

8. Defendants shall serve a copy of each DFS to Plaintiff's individual representative counsel as identified in the PFS, and to Plaintiffs' Liaison Counsel via E-mail (without attached documents produced) at:

Francisco Rodriguez
Goldsmith, Ctorides & Rodriguez, LLP
140 Sylvan Avenue
Englewood Cliffs, New Jersey 07632
fjr@goldsmithlegal.com

B. THE PRODUCTION OF SALES REPRESENTATIVE CUSTODIAL FILES

1. As set forth in Section II.B.6 of the DFS attached hereto as Exhibit 1, for all Sales Representatives or detail persons identified in Section II.B.2 of a particular DFS, copies of the sales representatives' custodial files are to be produced no later than **sixty (60) days** in advance of the first deposition noticed by Defendants specific to the action to which that DFS pertains.

2. Defendants shall produce to an individual Plaintiff's attorney a Sales Representative's custodial file reasonably promptly upon completion of collection and review of that individual file by Defendants' counsel, and shall not wait to produce one Sales Representative custodial file until all custodial files are collected and reviewed that pertain to an individual case. Nothing in this Case Management Order shall preclude the Plaintiff from noticing or taking any case-specific depositions without regard to the production of a Sales Representative's custodial file.

3. Sales Representative custodial files may include all written materials, video and or audio tapes in the possession of the Sales Representative identified in the DFS that had contact with Plaintiff's Dispensing/Prescribing Health Care Provider, including, but not limited to:

- (a) training materials (including videotapes and/or audio-tapes) related to physician detailing and obstacle handling, including any workbooks or forms completed by the Sales Representative at the time that he or she had Yaz®, Yasmin®, and/or Ocella®-related responsibilities;

- (b) e-mails, bulletins, memoranda, reports, activity reports, call notes, belief notes, tactical plans, voice-mail transcripts or summaries, meeting or conference summaries;
- (c) materials obtained at any national, regional, district or other sales meeting, including but not limited to written materials, videos and/or audio tape;
- (d) physician prescribing data and/or ratings;
- (e) incentive plans (to the extent the incentive plans specifically relate to Yaz®, Yasmin®, Ocella®, or drugs that are cross-promoted with Yaz®, Yasmin®, and/or Ocella®);
- (f) promotional or cross-promotional and marketing materials related to Yaz®, Yasmin®, and/or Ocella®;
- (g) all hardcopy generic training materials (including videotapes and audiotapes) related to physician detailing and obstacle handling, including any workbooks or forms completed by the Sales Representative;
- (h) all documents signed by the Sales Representative reflecting Defendants' business and or ethics practices and or policies at the time that he or she had Yaz®-, Yasmin®-, and/or Ocella®- related responsibilities;
- (i) all documents provided to Plaintiff's Dispensing/Prescribing Health Care Provider;
- (j) reports of goal attainment; plans, or action;
- (k) materials and information regarding budgets available for speaker's programs;
- (l) materials relating to speakers programs;

- (m) material relating to any testing taken by the Sales Representatives; and,
- (n) all communications by and between the Sales Representatives and managers.


4. Custodial files include all non-identical copies of the materials described above that are contained in the records of the identified Sales Representatives, whether those materials are stored and maintained by Defendants in its facilities, a third-party storage vendor, or at the home or automobile of the Sales Representative.

5. If there are any additions or changes to the DFS when Defendants produce the Sales Representative custodial file, Defendants shall provide Plaintiff's individual counsel and to Plaintiff Liaison Counsel at the e-mail address set forth in paragraph A(8) above with an Amended DFS clearly indicating the changes to the originally produced DFS. If there are no changes or additions to the DFS, Defendants shall indicate as much in the letter transmitting the Sales Representative custodial file.

C. BELLWETHER CASES

The parties shall meet and confer regarding any amendments to the provisions of this Order that may be appropriate with respect to any bellwether cases identified by the Court subsequent to the date of this Order, and shall present the Court with any appropriate amendments pertinent to such bellwether cases.

BY THE COURT



Hon. Brian R. Martinotti, J.S.C.

**SUPERIOR COURT OF NEW JERSEY
LAW DIVISION: BERGEN COUNTY**

**IN RE YAZ®, YASMIN®, OCELLA®
LITIGATION**

CASE NO. 287

CIVIL ACTION

This Document Relates to All Actions

DEFENDANTS' FACT SHEET

For each case, the Defendants must complete this Defendants' Fact Sheet ("DFS") and identify or provide documents and/or data relating to each Plaintiff responsive to the question set forth below to the best of Defendants' knowledge. In completing this DFS, you are under oath and must provide information that is true and correct to the best of your knowledge. If you cannot recall all of the details requested, please provide as much information as you can. The DFS shall be completed in accordance with the requirements and guidelines set forth in the applicable Case Management Order.

In the event the DFS does not provide you with enough space for you to complete your responses or answers, please attach additional sheets if necessary. Please identify any documents that you are producing as responsive to a question or request by Bates-stamp identifiers.

This DFS must be completed and served on all counsel representing a Plaintiff in the action identified in Section I below. This DFS must be answered and served by the date established by the Court in the Case Management Order implementing this DFS.

As used herein, the term "Documents" shall have the broadest possible meaning and interpretation and shall include, without limitation, any written, printed, typed, photostatic, photographed, recorded, computer generated, computer-stored, or otherwise maintained or reproduced communication or representation, any data compilation in any form, whether comprised of letters, words, numbers, pictures, sounds, bytes, emails, electronic signals or impulses, electronic data, active files, deleted files, file fragments, or any combination thereof including, without limitation, all memoranda, notes, records, letters, envelopes, telegrams, messages, studies, analyses, contracts, agreements, projections, estimates, working papers, accounts, analytical records, reports and/or summaries of investigations, opinions or reports of consultants, opinions or reports of experts, opinions or reports of accountants, other reports, trade letters, press releases, comparisons, books, diaries, articles, magazines, newspapers, booklets, brochures, pamphlets, circulars, bulletins, notices, forecasts, drawings, diagrams, instructions, minutes of meetings or communications of any type, including inter- and intra-office communications, questionnaires, surveys, charts, graphs, photographs, films, tapes, discs, data cells, drums, printouts, all other compiled data which can be obtained (translated, if necessary, through intermediary or other devices into usable forms), documents maintained on, stored in or generated on any electronic transfer or storage system, any primary versions, drafts or revisions of any of the foregoing, and other writings or documents of whatever description or kind, whether produced or authorized by or on behalf of you or anyone else, and shall include all non-identical copies and drafts of any of the foregoing now in the possession, custody or control of you, or your present directors, officers, counsel, agents, employees, partners, consultants, principals, and/or persons acting on your behalf Defendants are not required to identify or produce any pleading filed in litigation relating to Yaz®, Yasmin® or Ocella® or medical records produced in Plaintiff's individual case.

As used herein, the terms “you,” “your” or “yours” means all Defendants and any officers, agents, attorneys, employees, representatives or others acting on their behalf.

As used herein, the phrase “provided” means sold, distributed, shipped, delivered or otherwise placed into the stream of commerce.

As used herein, the term “communication” and/or “correspondence” shall mean and refer to any oral, written or electronic transmission of information, including, without limitation, meetings, discussions, conversations, telephone calls, memoranda, letters, e-mails, text messages, conferences, or seminars or any other exchange of information between Defendants or between you and any other person or entity.

Nothing in this DFS shall require Defendants to produce voice mail, instant messages, text messages, or be construed contrary to the requirements of the Case Management Order No. 2, governing the preservation of documents and electronically stored information, or any other Order, in this action.

As used herein, the phrase “Dispensing/Prescribing Health Care Provider” means each of Plaintiff’s physicians, medical providers, practices, clinics, persons or entities who prescribed or dispensed Yaz® / Yasmin® / Ocella® to Plaintiff as identified with particularity in the Plaintiff Fact Sheet (“PFS”).

As used herein, the phrase “anyone in their practice” means all employees of the clinic, practice, or group including, but not limited to, nurse practitioners, and/or other physicians that practice in the same office, group, or clinic with Plaintiff’s Dispensing/Prescribing Health Care Provider.

As used herein, the phrase “Promotional Items” means any and all promotion items, marketing devices, freebies, merchandise, handouts, meals, or any other items related to Yaz® / Yasmin® / Ocella® including but not limited to physical items marked with the Yaz® / Yasmin® / Ocella® trademark such as anatomical models, notepads, post-it-notes, pens, flashlights, other day-to-day office supplies of any type, models for patient demonstration, diagnostic tools and aids, medical assessment and dosage calculators, pharmacy and pharmacist tools, patient compliance tools, custom medical calculators and software, branded apparel (such as but not limited to shirts, hats, etc), leather portfolios, prescription pads, picture frames, letter openers, clipboards, water bottles, coffee mugs/cups, pocket/pen lights, key chains, badge-holders, bags, travel accessories, other “freebies” provided to Dispensing/Prescribing Health Care Providers (this list is not meant to be exhaustive). Promotional Items shall mean and include any and all cross-promotional materials related to Yaz® / Yasmin® / Ocella® jointly with other products or advertising campaigns.

As used herein, the term “identify” or “identity” with respect to persons, means to give, to the extent known, the person’s full name, and as to former employees or third-parties, their present or last known address.

As used herein, the term “person” means natural person, as well as corporate and/or governmental entity.

As used herein, the terms “relating to,” “relate to,” “referring to,” “refer to,” “reflecting,” “reflect,” “concerning,” or “concern” shall mean evidencing, regarding, concerning, discussing, embodying, describing, summarizing, containing, constituting, showing, mentioning, reflecting, pertaining to, dealing with, relating to, referring to in any way or manner, or in any way logically or factually, connecting with the matter described in that paragraph of these demands, including documents attached to or used in the preparation of or concerning the preparation of the documents.

As used herein, the term "possession, custody or control" shall mean and refer to any documents in your possession, custody or control. A document is deemed to be in your "possession, custody or control" if it is in your physical custody or if it is in the physical custody of another person or entity, and you: (a) own such document in whole or in part; or (b) have a legal right by contract, statute or otherwise to use, inspect, examine or copy such document on any terms. If Defendant is aware of documents responsive to a question/request in the DFS that are in the possession of a non-party but do not have a legal right to obtain the documents from the non-party, Defendant will identify the non-party and the nature of the documents in the response to the associated question/request in the DFS. Defendant Bayer Healthcare Pharmaceuticals, Inc. ("BHCP") shall produce information responsive to this DFS in the possession, custody and control of Intendis, Inc.

As used herein, the terms "Yaz," "Yasmin" or "Ocella" mean birth control drugs containing drospirenone, and any predecessor or non-final derivation of the drug that later became "YAZ®," "Yasmin®" or "Ocella®."

Unless otherwise indicated, the "relevant period" for the information sought is January 1, 1990 to the present.

Nothing herein prohibits the Defendant from withholding any materials or information protected by a claim of privilege. A privilege log shall be provided only to the extent of listing (i) any document responsive to this fact sheet that (ii) refers to the Plaintiff and/or the Dispensing/Prescribing Health Care Provider, and (iii) is withheld from production or from which any information has been redacted on a claim of attorney-client privilege or attorney work product protection. The privilege log shall not include documents and communications created in connection with or in the course of the defense of the action to which this DFS relates, but shall include all business documents and communications, including those created after the commencement of the action to which this DFS relates. As to any such document, specify the privilege or work product protection(s) you claim, and provide the following information: (a) the nature of the document (e.g., letter, memorandum, contract, etc.) and a description of its subject matter; (b) the author or sender of the document; (c) the recipient(s) of the document; (d) the date that the document was authored, sent and received; and (e) the basis for your privilege claim. If the claimed privilege or work product protection applies only to a particular phrase, sentence, paragraph, or section of a responsive document, the entire document should be produced with the allegedly protected portion redacted and a legend indicating that the withheld portion is a subject of a specified privilege or protection.

If you are aware that any document that was, or might have been, responsive to any sections of this DFS which concern or relate to Plaintiff or Plaintiff's Dispensing/Prescribing Health Care Provider was destroyed, erased, surrendered or otherwise removed from your possession, custody or control, at any time, provide, to the maximum extent possible, the following information: (a) the nature of the document (e.g., letter, memorandum, contract, etc.,) and a description of its subject matter; (b) the author or sender of the document; (c) the recipient(s) of the document; (d) the date that the document was authored, sent and received; (e) the circumstances surrounding the removal of the document from your custody, possession or control; and (f) the identity of the person(s) having knowledge of such removal from your custody, possession or control.

I.

CASE INFORMATION

This DFS pertains to the following case:

Case caption: _____

Civil Action No. _____

Court in which action was originally filed: _____

Date that this DFS was completed: _____

Name and Address of all persons who provided information responsive to the questions posed in this DFS:

A: _____
(Name)

(Address)

(Phone Number)

B: _____
(Name)

(Address)

(Phone Number)

II.

CONTACTS WITH DISPENSING/DISPENSING/PRESCRIBING HEALTH CARE PROVIDER

For each Dispensing/Prescribing Health Care Provider identified in the PFS, please state the following:

A. Dear Doctor Letters:

1. Please identify the "Dear Doctor" or "Dear Heath Care Provider" letter that you contend was actually sent to the Plaintiffs' Dispensing/Prescribing Health Care Provider concerning Yaz® / Yasmin® /Ocella®.

NOTE: Please attach hereto, to the extent available, a copy of each letter and the envelope or fax cover sheet in which it was allegedly sent to Plaintiff's Dispensing/Prescribing Health Care Provider.

2. For each "Dear Doctor" or "Dear Healthcare Provider" letter identified in Section II(A)(1) that you contend was actually sent to Plaintiff's Dispensing/Prescribing Health Care Provider, please state the date that each "Dear Doctor" or "Dear Heath Care Provider" letter was actually sent to Plaintiff's Dispensing/Prescribing Health Care Provider and the person to whom each letter was sent and the manner in which it was sent

3. For each "Dear Doctor" or "Dear Heath Care Provider" letter identified in Section II(A)(1) that you contend was actually sent to Plaintiff's Dispensing/Prescribing Health Care Provider, please provide or identify by Bates number any and all lists or databases which you contend demonstrates that these letters were actually sent and provide any proofs available of receipt of said letter(s).

4. Please identify the person or persons who provided information responsive to Section _____ or any of its subparts.

B. Other Contacts

- For each Dispensing/Prescribing Health Care Provider identified in the PFS, please produce or identify all contacts and communications between the Dispensing/Prescribing Health Care Provider and Defendants' Sales Representatives that relate to Yaz, Yasmin, Ocella, Premenstrual Syndrome ("PMS"), Premenstrual Dysphoric Disorder ("PMDD"), or acne.

Plaintiff's Dispensing/Prescribing Health Care Provider	Name and, if no longer employed by defendant, last known address and telephone number of Defendants' Sales Representative	Current employment status of Sales Representative	Date Range of Contacts

- For each Sales Representative or detail person that had contact with each Dispensing/Prescribing Healthcare Providers listed in the PFS regarding Yaz, Yasmin, Ocella Premenstrual Disorder ("PMS"), Premenstrual Dysphoric Disorder ("PMDD"), or acne. please provide the following information:

Plaintiffs Prescribing / Dispensing Health care Provider	Name of Sales Rep / Detail Person	Territory (ies) Covered	Date of Hire / Date Last Employed	Supervising District Manager(s) and, if no longer employed by defendant, last known address and telephone number	Supervising Field Sales Director current (or last known) and, if no longer employed by defendant, last known address and telephone number

3. For each Dispensing/Prescribing Health Care Provider, please state whether Defendants or their representatives ever provided him/her (or anyone in their practice) Yaz® / Yasmin® / Ocella® samples. If the answer is "yes," please state:
- (a) The number of sample packets provided and the dosages provided for each product;
 - (b) The dates that they were shipped and/or provided;
 - (c) The lot numbers for the samples provided on each date identified;
 - (d) The identity of the person or persons who provided the Samples;
 - (e) With regard to the region or territory, serviced or covered by any such representative, identify the allocation, or total amount and number of sample packets provided with regard to (a) – (c) above and whether or not additional samples were provided and the time frame during which such additional items were provided for said market.
4. For each Dispensing/Prescribing Health Care Provider, please state whether Defendants or their representatives ever provided him/her (or anyone in their practice) with "Promotional Items" (if available, a physical sample of each Promotional Item will be produced to Plaintiffs' Lead Counsel). If the answer is "yes," please state:
- (a) A description of each Promotional Item provided;
 - (b) The dates that each type of Promotional Item was delivered, shipped and/ or provided;
 - (c) The total quantity of each such Promotional Item delivered to each Dispensing/Prescribing Health Care Provider;
 - (d) The identity of the person or persons who provided the Promotional Item; and
 - (e) The fair market value of each such Promotional Item.
 - (f) With regard to the foregoing, please identify any and all instances where products, including but not limited to Yaz® / Yasmin® / Ocella® were promoted, marketed, advertised or offered, in conjunction with other products, or product lines and cross marketed. This includes, for example any gestational calendars, or other similar materials, that offered, marketed, promoted or advertised multiple items with modified or limited warnings. (i.e. Angelia, Yaz & Mirena).

5. For each Dispensing/Prescribing Health Care Provider, please produce any data or documents that identify whether Defendants or their representatives ever provided him/her (or anyone in their practice) with any type of documentation (including published studies or journal articles) relating in any way to the safety, efficacy, benefits, risks or on- or off-label use of Yaz® / Yasmin® / Ocella®, including, to the extent available:
 - (a) A description of each document provided;
 - (b) The dates that the document was mailed and/or provided; and,
 - (c) The identity of the person or persons who provided the documentation;
 - (d) A copy of any cover letters sent to Plaintiff's Dispensing/Prescribing Physician or anyone in their practice with the material.

6. For each Sales Representative or detail person identified in Section II(B)(2) above, produce a copy of the Sales Representative's custodial file relating to Yaz®, Yasmin® or Ocella® no later than 60 days in advance of the first deposition specific to this action that is noticed by Defendants, including:
 - (a) Any and all notes or other documents of that person or persons, including all personal notes, calendar entries, computer entries, that reflects or refers to any communications with any of Plaintiff's Dispensing/Prescribing Health Care Providers.
 - (b) Any and all notes or other documents of that person or persons, including all personal notes, calendar entries, computer entries, backgrounder documents, marketing information or other documents referred to in the sales call notes and other materials that is/ was in their possession concerning Yaz® / Yasmin® / Ocella®.
 - (c) Any and all information including promotional information, that the Sales Representative or detail person distributed to any of Plaintiff's Dispensing/Prescribing Health Care Providers or any provider in the practice.

7. Please identify the person or persons who provided information responsive to Section II or any of its subparts.

III. CONSULTING WITH PLAINTIFF'S DISPENSING/PRESCRIBING HEALTH CARE PROVIDER

- A. If you have ever retained any of the Dispensing/Prescribing Health Care Providers listed in the PFS as a "thought leader," "Key Opinion Leader", a member of a "speaker's bureau," a "clinical investigator," a "consultant" or in any other capacity on the subject of Yaz® / Yasmin® / Ocella®, Premenstrual Syndrome ("PMS"), Premenstrual Dysphoric Disorder (PMDD), or the treatment of acne, please provide the following information:

Name of Plaintiff's Dispensing/Prescribing Health Care Provider who was retained by Defendants	Date(s) he or she was retained	All records of any documents relating Yaz, Yasmin and/Ocella, PMS, PMDD or acne as related to these products provided to Dispensing/Prescribing Health Care Provider by Defendants

- B. For each Dispensing/Prescribing Health Care Provider identified in the PFS (regardless of whether included in Section III(A) above or not), please state how much money you have paid to them, whether for expenses, honoraria, fees, or any other payment, for each calendar year, and produce the 1099s or, if unavailable, other documents or data sufficient to evidence such payments:

- C. For each Dispensing/Prescribing Health Care Providers identified in Section III(B) above, please identify or provide all consulting agreements and contracts.
- D. For each Dispensing/Prescribing Health Care Providers identified in the PFS, please state whether they ever attended any Defendant-sponsored conferences or events ("Programs") relating to Yaz, Yasmin, Ocella, PMS, PMDD or acne. If your answer is "yes," please state:

Identity of the Dispensing/Prescribing Health Care Provider	Title, location and date of the Program attended	Topic of the Program	All speakers at the Program	Please provide or identify the agenda/brochure for the Program

- E. Have Plaintiff's Dispensing/Prescribing Health Care Providers ever contacted you to request information concerning Yaz® / Yasmin® / Ocella®, its indications, its effects and/or its risks?

Yes No

If "Yes," please identify and attach any document that refers to your communication with Plaintiff's Dispensing/Prescribing Health Care Providers and/or any document that was provided to Plaintiff's Dispensing/Prescribing Health Care Providers in response to such request for information.

- F. Please identify the person or persons who provided information responsive to Section III or any of its subparts, giving their name, address, telephone number indicating whether said person is currently an employee of Defendants and/or any of its subsidiaries and the dates of employment.

IV. PLAINTIFF'S DISPENSING/PRESCRIBING HEALTH CARE PROVIDER'S DISPENSING/PRESCRIBING PRACTICES

For each Dispensing/Prescribing Health Care Provider identified in the PFS, please state and produce the following:

- A. Do you have or have you had access to any database or information which purports to track the dispensing/prescribing practices of any Dispensing/Prescribing Health Care Providers listed in the PFS with respect to Yaz® / Yasmin® / Ocella® or any other combination contraceptive drug (including, but not limited to the product(s) prescribed, the number of prescriptions, the number of refills and the time frame when these products were prescribed or refilled).

Yes No

If your answer is "Yes," please produce or identify the database or document that captures that information:

- B. Please identify the person or persons who provided information responsive to Section IV or any of its subparts.

V.

PLAINTIFF'S MEDICAL CONDITION

A. Other than in connection with any adverse event report, have you initiated contact with any of Plaintiff's physicians concerning Plaintiff's injuries?

_____ Yes

_____ No

B. Other than in connection with any adverse event report, have you been contacted by Plaintiff, any of her physicians, or anyone on behalf of Plaintiff concerning Plaintiff (other than counsel for plaintiff)?

_____ Yes

_____ No

C. If your answer to A or B above is "Yes," please state the name, address and telephone number of these individuals.

Name	Address	Phone

D. Please produce any non-privileged documents that reflect any communication between Plaintiff, any of her physicians, or anyone on behalf of Plaintiff (other than counsel for plaintiff, and you, concerning Plaintiff.

E. Please produce a copy of any MedWatch form which refers or relates to Plaintiff, including back-up documentation concerning Plaintiff and any evaluation or investigation you did concerning the Plaintiff.

F. Please identify the person or persons who provided information responsive to Section V or any of its subparts.

VI. ADVERTISING

1. Aside from national advertising (i.e., advertising buys that were not directed in any way to specific regions), did you advertise Yaz® / Yasmin® / Ocella® in the Media Market of where Plaintiff resided at, or within 6 months of, the time she used Yaz® / Yasmin® / Ocella®?

_____ _____
 Yes No

2. If your answer is “yes,” please provide the following information:

Identity of the Advertisement	Nature of media (print or television)	Identify the media outlet	Dates that advertisements ran

Please provide or identify true and accurate copies of any advertisement identified above.

3. Aside from national advertising, did you advertise Yaz® / Yasmin® / Ocella® in the Media Market of any of the Dispensing/Prescribing Health Care Providers’ office locations listed on the PFS at, or within 6 months of, the time that Plaintiff used Yaz® / Yasmin® / Ocella®?

_____ _____
 Yes No

4. If your answer to the preceding question is "Yes," please provide the following information:

Identity of the Advertisement	Nature of media (print or television)	Identify the media outlet	Dates that advertisements ran; Prescriber/Dispenser on PFS within 100 miles

Please provide or identify true and accurate copies of any advertisement identified above.

5. Was the Plaintiff registered with any program owned, operated or controlled by Defendant whereby Plaintiff received electronic communications concerning Yaz® / Yasmin® / Ocella®? If your answer is yes, identify or produce documents describing such program and reflecting any communications with the Plaintiff.

VII. THIRD PARTIES

- A. Name each and every party whom you believe is a necessary and proper party to this litigation.

- B. Name each and every party whom you believe caused or contributed to the injuries or damages of Plaintiff.

VIII. DOCUMENTS

- A. To the extent you have not already done so, please produce a copy of all documents and things in your possession, custody and control that fall into the categories listed below.
1. Any non-privileged document which relates to or refers to Plaintiff other than documents received or produced in discovery in this matter, and subject to the limitations and exceptions described in this DFS. .
 2. Any document sent to or received from any of Plaintiff's Dispensing/Prescribing Health Care Providers relating to Yaz® / Yasmin® / Ocella®, subject to the limitations and exceptions described in this DFS.
 3. Any document reflecting any actual communication between you and Plaintiff's Dispensing/Prescribing Health Care Providers concerning the topics identified in Section III(F), subject to the limitations and exceptions described in this DFS.
 4. Any documents reflecting any contacts or actual communications between you and any of Plaintiff's Dispensing/Prescribing Health Care Providers regarding Yaz® / Yasmin® / Ocella®, subject to the limitations and exceptions described in this DFS.
 5. Any document which reflects or purports to describe the Dispensing/Prescribing practices of any of Plaintiff's Dispensing/Prescribing Health Care Providers relating to Yaz®, Yasmin®, Ocella®, PMDD, or acne, subject to the approval or agreement of the owner of the prescribing data to release the data.
 6. Any and all documents requested or referred to in Sections I-VII, above.

CERTIFICATION

I am authorized to make this Certification on behalf of _____. The information provided in the foregoing Defendant Fact Sheet has been compiled by employees and legal counsel for _____. Although I do not have personal knowledge of all of the information set forth therein, I declare under penalty of perjury that the foregoing is true and correct to the best of my knowledge, understanding and belief, formed after due diligence and reasonable inquiry.

Signature

Print Name

Date

FP01/ 6333377.1